Alain CornetAt the recent American Congress of Rheumatology in San Fransisco this week, we received fantastic news on two promising trial results. 1. AstraZeneca Phase IIb Anifrolumab 300 mg showed positive results, where it produced a response in 34.4 percent of patients after 169 days of treatment and this rose to more than 50 percent after […]
Alain CornetThis is just a reminder that the December deadline for patient stories is fast approaching. If you are a member of one of our patient organisations and want to share your story please send it to katharine@lupus-europe.org
Alain CornetEPF is launching a second consultation on a draft position on defining and measuring access to healthcare. The position paper was developed with the working group on access. The first consultation was held in September/October. Lupus Europe is involved in this working group and your input to the consultation would be much appreciated if you […]